Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate

Imatinib mesylate (IM) is a small molecule inhibitor of protein tyrosine kinases. In addition to its direct effect on malignant cells, it has been suggested IM may activate of natural killer (NK) cells, hence exerting immunomodulatory functions. In preclinical settings, improved antitumor responses...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Pautier, Patricia, Locher, Clara, Robert, Caroline, Deroussent, Alain, Flament, Caroline, Le Cesne, Axel, Rey, Annie, Bahleda, Ratislav, Ribrag, Vincent, Soria, Jean-Charles, Vassal, Gilles, Eggermont, Alexander, Zitvogel, Laurence, Chaput, Nathalie, Paci, Angelo
Médium: Artigo
Jazyk:Inglês
Vydáno: Landes Bioscience 2013
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3601177/
https://ncbi.nlm.nih.gov/pubmed/23525192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.23079
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky